Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPTGet Free Report) have been assigned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $164.00.

A number of research analysts have weighed in on SRPT shares. Barclays increased their target price on Sarepta Therapeutics from $141.00 to $185.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Citigroup boosted their target price on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Piper Sandler began coverage on shares of Sarepta Therapeutics in a research report on Friday, May 31st. They issued an “overweight” rating and a $157.00 price target on the stock. Mizuho lifted their price target on shares of Sarepta Therapeutics from $145.00 to $179.00 and gave the stock a “buy” rating in a research note on Friday, May 17th. Finally, TheStreet upgraded Sarepta Therapeutics from a “d” rating to a “c-” rating in a research note on Monday, March 4th.

Read Our Latest Report on Sarepta Therapeutics

Insider Buying and Selling

In other Sarepta Therapeutics news, insider Dallan Murray sold 3,635 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total transaction of $508,900.00. Following the completion of the sale, the insider now directly owns 18,125 shares of the company’s stock, valued at approximately $2,537,500. The sale was disclosed in a legal filing with the SEC, which is available at this link. 7.70% of the stock is owned by insiders.

Institutional Trading of Sarepta Therapeutics

Several hedge funds have recently bought and sold shares of SRPT. Mather Group LLC. bought a new stake in shares of Sarepta Therapeutics in the first quarter worth about $28,000. Riggs Asset Managment Co. Inc. increased its stake in Sarepta Therapeutics by 125.0% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 125 shares during the last quarter. New Covenant Trust Company N.A. purchased a new stake in shares of Sarepta Therapeutics during the 1st quarter worth approximately $32,000. Cary Street Partners Investment Advisory LLC raised its holdings in shares of Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 154 shares in the last quarter. Finally, Principal Securities Inc. bought a new position in shares of Sarepta Therapeutics during the 4th quarter valued at approximately $26,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $117.52 on Friday. The company has a quick ratio of 3.44, a current ratio of 4.05 and a debt-to-equity ratio of 1.18. The company has a 50 day moving average price of $125.00 and a 200-day moving average price of $119.19. Sarepta Therapeutics has a 52 week low of $55.25 and a 52 week high of $146.68. The firm has a market capitalization of $11.11 billion, a PE ratio of 1,068.36 and a beta of 0.96.

Sarepta Therapeutics (NASDAQ:SRPTGet Free Report) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.84. The company had revenue of $413.50 million for the quarter, compared to analysts’ expectations of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The firm’s quarterly revenue was up 63.1% on a year-over-year basis. During the same quarter last year, the company posted ($1.44) earnings per share. As a group, equities research analysts expect that Sarepta Therapeutics will post 2.99 earnings per share for the current year.

About Sarepta Therapeutics

(Get Free Report

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

See Also

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.